MedyMatch Technology Ltd and Samsung NeuroLogica Corporation recently announced a collaboration to integrate artificial intelligence (AI) clinical decision support applications with Samsung NeuroLogica’s medical imaging hardware in the acute care marketplace. This collaboration will create support tools that provide a second read capability to help caregivers quickly and accurately assess patients in prehospital environments.

The first focus area will be in the enhancement of stroke assessment, specifically, with integration of MedyMatch’s AI technologies into the mobile stroke unit, a specialized ambulance or other emergency vehicle that is equipped with a Samsung NeuroLogica CereTom computed tomography (CT) scanner. The mobile unit with diagnostic CT imaging capabilities is designed to allow the team onboard to quickly assess whether a patient is having a stroke caused by a blood clot or hemorrhage.

The very first step in patient assessment is to rule out the presence of a brain bleed, and this is where MedyMatch’s technology will be utilized, pending regulatory approval to provide decision support.

“We are on the threshold of the next evolutionary step in imaging,” says Gene Saragnese, chairman and CEO of MedyMatch, “Imaging technological development has been historically focused on providing clinicians the best possible image, optimizing spatial and temporal resolution, coverage, and dose; however, MedyMatch’s artificial intelligence applications will leap this paradigm forward, enabling imagers such as CT to provide clinical answers and not just images.”

“This is just one example of how intelligent imaging can have a positive impact on a stroke or trauma patient and provide a whole new level of care by bringing ‘AI to the curbside,'” says Robert Mehler, chief operating officer of MedyMatch. “MedyMatch envisions that medical imaging devices will be AI-enabled with decision support to assist the physician in patient care, increase the speed in which patient assessment can be performed, and optimize the clinical workflow.”

“Samsung is committed to bringing innovative technology to the marketplace to improve patient outcomes,” says Phillip Sullivan, president and CEO of Samsung NeuroLogica. “Our CereTom-equipped mobile stroke units are at the forefront of that commitment. We are seeing worldwide demand and implementation of our mobile stroke units, with new installations in New York, Trenton, Chicago, Bangkok, Alberta, India, and Germany. Our collaboration with MedyMatch is one more step forward in advanced technology to support better treatment of stroke.”

For more information, visit MedyMatch or Samsung NeuroLogica.